112 related articles for article (PubMed ID: 1908533)
21. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
22. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
23. Higher susceptibility of erythropoietin-producing renal cell carcinomas to lysis by lymphokine-activated killer cells.
Miyajima J; Imai Y; Nakao M; Noda S; Itoh K
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):399-404. PubMed ID: 9041458
[TBL] [Abstract][Full Text] [Related]
24. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
[TBL] [Abstract][Full Text] [Related]
25. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
[TBL] [Abstract][Full Text] [Related]
26. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
[TBL] [Abstract][Full Text] [Related]
27. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
28. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
29. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
[TBL] [Abstract][Full Text] [Related]
30. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
Reiter Z
J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
[TBL] [Abstract][Full Text] [Related]
31. Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment.
Miyatake S; Kikuchi H; Oda Y; Nishioka T; Takahashi J; Kondoh S; Matsumoto M; Yamasaki T; Iwasaki K; Aoki T
Cancer Res; 1990 Feb; 50(3):596-600. PubMed ID: 2137025
[TBL] [Abstract][Full Text] [Related]
32. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.
Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D
Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997
[TBL] [Abstract][Full Text] [Related]
33. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
[TBL] [Abstract][Full Text] [Related]
34. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
35. Role of major histocompatibility complex class I antigens in modulating the performance of murine tumour cells in cold target competition assays.
Haridas V; Saxena RK
Immunology; 1995 Jan; 84(1):86-90. PubMed ID: 7890307
[TBL] [Abstract][Full Text] [Related]
36. Low-dose human cytomegalovirus infection of human fibroblast cultures induces lymphokine-activated killer cell resistance: interferon-beta-mediated target cell protection does not correlate with up-regulation of HLA class I surface molecules.
Hamprecht K; Steinmassl M
Immunology; 1994 Jun; 82(2):171-7. PubMed ID: 7927485
[TBL] [Abstract][Full Text] [Related]
37. MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: possible implications for the existence of LAK cell subpopulations using different recognition strategies.
Sarin A; Haridas V; Saxena RK
Immunol Lett; 1993 Sep; 38(1):59-62. PubMed ID: 8300155
[TBL] [Abstract][Full Text] [Related]
38. [Expression on major histocompatibility complex antigen and effect of IFN-alpha on renal cell carcinoma].
Nagata M
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):814-21. PubMed ID: 8320886
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.
Lobo PI; Chang MY; Mellins E
Immunology; 1996 Aug; 88(4):625-9. PubMed ID: 8881767
[TBL] [Abstract][Full Text] [Related]
40. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
